{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T07:29:39Z","timestamp":1782890979663,"version":"3.54.5"},"reference-count":15,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2020,8,17]],"date-time":"2020-08-17T00:00:00Z","timestamp":1597622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Scott Med J"],"published-print":{"date-parts":[[2020,11]]},"abstract":"<jats:p>The use of angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin-receptor blockers (ARBs) in patients with Coronavirus 2019 (COVID-19) has been controversial. We performed a meta-analysis of all published studies that reported the outcomes of ACEIs\/ARBs in patients with COVID-19. We included four observational studies (3,267 patients). The use of ACEIs\/ARBs was associated with a similar risk of all-cause death (OR: 0.75, 95% CI [0.36, 1.57], p\u2009=\u20090.45). Sensitivity analysis including only hypertensive patients demonstrated a lower risk of death with ACEIs\/ARBs use (OR: 0.57, 95% CI [0.32-0.98], p\u2009=\u20090.04). In conclusion, hypertensive patients with COVID-19 treated with ACEIs\/ARBS have a lower mortality but further research is needed.<\/jats:p>","DOI":"10.1177\/0036933020949219","type":"journal-article","created":{"date-parts":[[2020,8,18]],"date-time":"2020-08-18T01:27:32Z","timestamp":1597714052000},"page":"123-126","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":17,"title":["Renin-angiotensin system antagonists are associated with lower mortality in hypertensive patients with COVID-19"],"prefix":"10.1177","volume":"65","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3176-6677","authenticated-orcid":false,"given":"Michael","family":"Megaly","sequence":"first","affiliation":[{"name":"Interventional cardiology fellow, Minneapolis Heart Institure, Abbott Northwestern Hospital, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mattew","family":"Glogoza","sequence":"additional","affiliation":[{"name":"Internal medicine resident, Abbott Northwestern Hospital, Minneapolis, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2020,8,17]]},"reference":[{"key":"bibr1-0036933020949219","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30566-3"},{"key":"bibr2-0036933020949219","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2002032"},{"key":"bibr3-0036933020949219","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2020.1624"},{"key":"bibr4-0036933020949219","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00127-20"},{"key":"bibr5-0036933020949219","doi-asserted-by":"publisher","DOI":"10.1093\/ajh\/hpu086"},{"key":"bibr6-0036933020949219","doi-asserted-by":"publisher","DOI":"10.1001\/jama.283.15.2008"},{"key":"bibr7-0036933020949219","doi-asserted-by":"publisher","DOI":"10.1080\/22221751.2020.1746200"},{"key":"bibr8-0036933020949219","volume":"126","author":"Zhang P","year":"2020","journal-title":"Circ Res"},{"key":"bibr9-0036933020949219","doi-asserted-by":"crossref","unstructured":"Mehta N, Kalra A, Nowacki AS, et\u00a0al. Association of use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers with testing positive for coronavirus disease 2019 (COVID-19).\n                      JAMA Cardiol\n                      2020. Epub ahead of print 5 May 2020. DOI: 10.1001\/jamacardio.2020.1855","DOI":"10.1001\/jamacardio.2020.1855"},{"key":"bibr10-0036933020949219","doi-asserted-by":"publisher","DOI":"10.1038\/nature03712"},{"key":"bibr11-0036933020949219","doi-asserted-by":"publisher","DOI":"10.1038\/nm1267"},{"key":"bibr12-0036933020949219","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30628-0"},{"key":"bibr13-0036933020949219","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2021225"},{"key":"bibr14-0036933020949219","unstructured":"Losartan for Patients With COVID-19 Not Requiring Hospitalization, https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT04311177 (2020, accessed 29 July 2020)"},{"key":"bibr15-0036933020949219","unstructured":"Losartan for Patients With COVID-19 Requiring Hospitalization, https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04312009 (2020, accessed 29 July 2020)"}],"container-title":["Scottish Medical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0036933020949219","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/0036933020949219","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0036933020949219","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T10:19:31Z","timestamp":1777630771000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/0036933020949219"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,17]]},"references-count":15,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["10.1177\/0036933020949219"],"URL":"https:\/\/doi.org\/10.1177\/0036933020949219","relation":{},"ISSN":["0036-9330","2045-6441"],"issn-type":[{"value":"0036-9330","type":"print"},{"value":"2045-6441","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,17]]}}}